Harnessing nanotechnology for enhanced delivery of erlotinib: a dynamic duo in cancer treatment

Pahwa, R; Saini, S; Chhabra, J; Goyal, R; Kumar, S; Awasthi, R; Dureja, H

Harnessing nanotechnology for enhanced delivery of erlotinib: a dynamic duo in cancer treatment

Pahwa, R Saini, S Chhabra, J Goyal, R Kumar, S Awasthi, R Dureja, H

Permalink

Publisher:: Springer Nature
Publication Type:: Journal Article
Citation:: Beni-Suef University Journal of Basic and Applied Sciences, 2024, 13, (1), pp. 69
Issue Date:: 2024-12-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.71 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Pahwa, R
dc.contributor.author	Saini, S
dc.contributor.author	Chhabra, J
dc.contributor.author	Goyal, R
dc.contributor.author	Kumar, S
dc.contributor.author	Awasthi, R
dc.contributor.author	Dureja, H
dc.date.accessioned	2024-11-19T03:52:49Z
dc.date.available	2024-11-19T03:52:49Z
dc.date.issued	2024-12-01
dc.identifier.citation	Beni-Suef University Journal of Basic and Applied Sciences, 2024, 13, (1), pp. 69
dc.identifier.issn	2314-8535
dc.identifier.issn	2314-8543
dc.identifier.uri	http://hdl.handle.net/10453/181985
dc.description.abstract	Erlotinib is a reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that acts by inhibiting signaling pathways, resulting in the disruption of cancerous cell proliferation. Erlotinib is a promising anticancer agent mainly utilized in the mitigation of non-small cell lung cancer cells (NSCLC) and pancreatic tumor. Apart from NSCLC and pancreatic tumor, erlotinib has also been employed in different malignancies, including metastatic colorectal cancer, malignant glioma, breast cancer, gastrointestinal cancers, etc. Despite erlotinib’s distinctive qualities as a targeted drug, its applications are still limited by poor solubility, variable oral bioavailability, a high daily dose requirement, large protein binding, and primitive or acquired therapeutic resistance. Nanotechnology is a favorable approach to increase therapeutic effectiveness of erlotinib. It is one of the newest scientific field directed toward the diagnosis and targeted treatment of cancer. This technology aids in the distinction between normal and malignant cells, which overlays the strategy for targeted delivery. This manuscript discussed the advances of erlotinib nanoformulations in the management of different cancers. Moreover, the manuscript also comprises various research outcomes of erlotinib nanoformulations with other therapeutic agents as combinational therapy. Erlotinib can be delivered to a precise target in the body utilizing different polymers, lipids, and metals.
dc.language	en
dc.publisher	Springer Nature
dc.relation.ispartof	Beni-Suef University Journal of Basic and Applied Sciences
dc.relation.isbasedon	10.1186/s43088-024-00528-3
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Harnessing nanotechnology for enhanced delivery of erlotinib: a dynamic duo in cancer treatment
dc.type	Journal Article
utslib.citation.volume	13
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/Faculty of Health/School of Public Health
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2024-11-19T03:52:47Z
pubs.issue	1
pubs.publication-status	Accepted
pubs.volume	13
utslib.citation.issue	1

Abstract:

Erlotinib is a reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that acts by inhibiting signaling pathways, resulting in the disruption of cancerous cell proliferation. Erlotinib is a promising anticancer agent mainly utilized in the mitigation of non-small cell lung cancer cells (NSCLC) and pancreatic tumor. Apart from NSCLC and pancreatic tumor, erlotinib has also been employed in different malignancies, including metastatic colorectal cancer, malignant glioma, breast cancer, gastrointestinal cancers, etc. Despite erlotinib’s distinctive qualities as a targeted drug, its applications are still limited by poor solubility, variable oral bioavailability, a high daily dose requirement, large protein binding, and primitive or acquired therapeutic resistance. Nanotechnology is a favorable approach to increase therapeutic effectiveness of erlotinib. It is one of the newest scientific field directed toward the diagnosis and targeted treatment of cancer. This technology aids in the distinction between normal and malignant cells, which overlays the strategy for targeted delivery. This manuscript discussed the advances of erlotinib nanoformulations in the management of different cancers. Moreover, the manuscript also comprises various research outcomes of erlotinib nanoformulations with other therapeutic agents as combinational therapy. Erlotinib can be delivered to a precise target in the body utilizing different polymers, lipids, and metals.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/181985